Cargando…

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

BACKGROUND: The burden of non-small cell lung cancer (NSCLC) remains high in Spain, with lung cancer accounting for 20% of cancer-related deaths annually. Programs such as the Spanish Thoracic Tumour Registry (TTR) and the global I-O Optimise initiative have been developed to observe patients in cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provencio, Mariano, Carcereny, Enric, López Castro, Rafael, Calvo, Virginia, Rodríguez Abreu, Delvys, Cobo, Manuel, Ortega, Ana Laura, Bernabé, Reyes, Guirado, Maria, Massutí, Bartomeu, del Barco-Morillo, Edel, Bosch-Barrera, Joaquim, Camps, Carlos, Carroll, Robert, Rault, Caroline, Chaib, Carlos, Penrod, John, Vo, Lien, Ralphs, Eleanor, Daumont, Melinda J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654433/ https://www.ncbi.nlm.nih.gov/pubmed/38025806 http://dx.doi.org/10.21037/tlcr-23-176

Ejemplares similares

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study
por: Ruano-Ravina, Alberto, et al.
Publicado: (2021)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Lung cancer symptoms at diagnosis: results of a nationwide registry study
por: Ruano-Raviña, Alberto, et al.
Publicado: (2020)

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative
por: Snee, Michael, et al.
Publicado: (2021)

Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative
por: Snee, Michael, et al.
Publicado: (2021)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I‐O Optimise initiative
por: Soares, Marta, et al.
Publicado: (2021)

Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results‐Medicare data
por: Danese, Mark D., et al.
Publicado: (2021)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
por: Campbell, David, et al.
Publicado: (2018)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
por: Provencio, Mariano, et al.
Publicado: (2022)

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
por: Verleger, Katharina, et al.
Publicado: (2020)

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative
por: Soares, Marta, et al.
Publicado: (2020)

Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database
por: Soares, Marta, et al.
Publicado: (2021)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
por: Majem, M., et al.
Publicado: (2018)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis
por: Carroll, Robert, et al.
Publicado: (2022)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
por: Campos‐Balea, Begoña, et al.
Publicado: (2020)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
por: De las Peñas, Ramón, et al.
Publicado: (2015)

Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
por: Franco, Fernando, et al.
Publicado: (2021)

Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative
por: Ekman, Simon, et al.
Publicado: (2021)

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018
por: Wolf, Andrea, et al.
Publicado: (2023)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
por: García-Campelo, R., et al.
Publicado: (2015)

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
por: Provencio, Mariano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2drffrmqjbmtmhhq85a9711nrq